PPCB
Propanc Biopharma, Inc.
NASDAQ · Healthcare · Biotechnology · AU
$1.82
+6.51%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$1.77
From 52W high−93.83%
Volume8395.00
Market cap$1.88M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$1.77
From 52W high
−93.83%
Volume
8395.00
Market cap
$1.88M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.1x
P/E (TTM)
—
RSI (14)
26.3
MomentumView details →
1D Return
+6.51%
YTD Return
−86.18%
Similar companies
Latest newsMore news →
Propanc Biopharma filed an Australian patent application relating to combining its pancreatic proenzyme formulation with galunisertib.2d agoPropanc Biopharma said it received a NASDAQ, INC. notice concerning noncompliance with the minimum bid price requirement and intends to request an appeal by October 30, 2026.6d agoPropanc Biopharma, Inc. advanced preparations for a planned PRP Phase 1b first-in-human study involving up to 50 patients with advanced cancer.7d ago